RTH dose prescribed | |||||
---|---|---|---|---|---|
Characteristics | All (n = 277,100%) | 70Gy (n = 30, 10.8%) | 74Gy (n = 177, 63.9%) | 80Gy (n = 70, 25.3%) | p-value |
Age (years) | 69 (51–79) | 70 (56;79) | 71 (51;79) | 68.5 (51;76) | 0.03 |
Follow up (months) | 53.1 (3.4–150) | 48.4 (3.9;94.8) | 47.1 (3.4;150.2) | 75.6 (7.8;131.7) | <0.01 |
PSA level (ng/ml) | |||||
<10 | 166 (59.9%) | 26 (86.7%) | 105 (59.4%) | 35 (50%) | <0.01 |
10–20 | 79 (28.5%) | 3 (10%) | 19 (10.7%) | 10 (14.3%) | |
>20 | 32 (11.6%) | 1 (3.3%) | 53 (29.9%) | 25 (35.7%) | |
Gleason | |||||
6 | 88 (32.1%) | 23 (76.7%) | 46 (26.3%) | 19 (27.5%) | <0.01 |
7 (3 + 4) | 84 (30.7%) | 4 (13.3%) | 52 (29.7%) | 28 (40.6%) | |
7 (4 + 3) | 60 (21.9%) | 1 (3.3%) | 47 (26.9%) | 12 (17.4%) | |
8–10 | 42 (15.3%) | 2 (6.7%) | 30 (17.1%) | 10 (14.5%) | |
Tumor stage | |||||
T1-T2a | 178 (64.3%) | 25 (83.3%) | 110 (62.2%) | 43 (61.4%) | 0.15 |
T2b | 44 (15.9%) | 3 (10%) | 27 (15.3%) | 14 (20%) | |
T2c-T4 | 55 (19.9%) | 2 (6.7%) | 40 (22.5%) | 13 (18.6%) | |
D’Amico risk group | |||||
Low risk | 41 (14.8%) | 20 (66.7%) | 20 (11.3%) | 1 (1.4%) | <0.01 |
Intermediate risk | 161 (58.1%) | 7 (23.3%) | 103 (58.2%) | 51 (72.9%) | |
High risk | 75 (27.1%) | 3 (10%) | 54 (30.5%) | 18 (25.7%) | |
Androgen deprivation | |||||
No | 149 (53.9%) | 23 (76.7%) | 90 (50.9%) | 36 (51.4%) | 0.03 |
Yes | 128 (46.1%) | 7 (23.3%) | 87 (49.1%) | 34 (48.6%) | |
Short (< 6 months) | 70 (25.4%) | 4 (13.3%) | 38 (21.7%) | 28 (40%) | <0.01 |
Long (> 6 months) | 57 (20.7%) | 3 (10%) | 48 (27.4%) | 6 (8.6%) | |
IPSS baseline | |||||
0–7 | 236 (85.2%) | 24 (80%) | 154 (87%) | 58 (82.9%) | 0.49 |
≥8 | 41 (14.8%) | 6 (20%) | 23 (13%) | 12 (17.1%) | |
Diabetes | |||||
Yes | 49 (17.9%) | 5 (16.7%) | 33 (18.9%) | 11 (15.9%) | 0.85 |
Coronary disease | |||||
Yes | 46 (16.9%) | 5 (18.5%) | 31 (17.6%) | 10 (14.5%) | 0.82 |
High blood pressure | |||||
Yes | 151 (54.9%) | 18 (60%) | 98 (55.7%) | 35 (50.7%) | 0.66 |
Surgery | |||||
Abdominal | 29 (10.5%) | 6 (20%) | 17 (9.6%) | 6 (8.6%) | 0.19 |
Pelvic | 86 (31.1%) | 2 (6.7%) | 46 (26%) | 38 (54.3%) | <0.01 |
Other | 46 (16.7%) | 7 (23.3%) | 28 (15.8%) | 11 (15.7%) | 0.57 |
Transurethral resection of prostate | |||||
Yes | 38 (13.8%) | 20% (6) | 14.29% (25) | 10% (7) | 0.40 |
Alpha blocker treatment at D-1 RTH | |||||
Yes | 57 (20.7%) | 6 (20%) | 44 (25.1%) | 11 (15.7%) | 0.26 |
Anticoagulant or antiplatelet treatment | |||||
Yes | 112 (40.7%) | 11 (36.7%) | 78 (44.6%) | 23 (32.9%) | 0.21 |